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Aims: Blastocystis is an anaerobic, enteric, protistan parasite
with zoonotic potential. Its clinical relevance has been de-
bated extensively, as some studies support a pathogenic role
for the parasite while others show no correlation between in-
fection and disease. Humans can be infected by a variety of
distinct genotypes (subtypes). We hypothesize that subtypes vary
in pathogenic potential and we aimed to investigate if such
differences can be observed using in vitro cytopathic assays.
Methods & Results: Investigations were carried on Blastocystis
subtypes 4 and 7, which are zoonotic genotypes found in ro-
dent and avian hosts respectively. Cysteine protease activity was
determined by azocasein assay. The results revealed inter- and
intra-subtype variations in protease activity, with subtype 7 iso-
lates harboring higher cysteine protease levels. Apoptosis assays
for phosphatidylserine (PS) externalization and nuclear blebbing
revealed that subtype 7 induced more cell death in host cells
than subtype 4. Similarly, transwell assays for barrier function
showed that subtype 7 induced greater barrier disruption than
subtype 4. A stress ﬁber model developed in Caco-2 colonic ep-
ithelial cells, revealed that subtype 7 induced reorganization of
stress ﬁbers with a possible link to barrier function compromise.
Conclusions: From this study, clear cytopathic differences exist
between Blastocystis subtypes, which suggest that variations in
pathogenic potential exists among Blastocystis genotypes from
different animal hosts.
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Several epidemic outbreaks of Enterovirus 71 (EV71) infection oc-
curred during the past one decade in southern Taiwan. EV71 has
the potential to cause a large outbreak worldwide such as that
in Taiwan in 1998. The main clinical presentations are herpang-
ina, hand-foot-and-mouth disease (HFMD), and central nervous
system (CNS) complications. Brain stem encephalitis (BE) is the
cardinal feature of EV71 CNS complications during the outbreak.
The predominant neurological presentations are myoclonus jerk,
vomiting, and ataxia. BE that progressed abruptly to neurogenic
shock and pulmonary edema (PE) was indicative of poor prognosis
and high mortality. EV71 BE was categorized into uncomplicated
BE, autonomic nervous system (ANS) dysregulation, and PE by
disease severity. The PE that occurs in children with EV71 BE is
caused by abnormal cytokines activation that produces severe
CNS and systemic inﬂammatory responses. Currently, there is
no speciﬁc antiviral agent to treat or vaccine to prevent EV71
diseases. Intravenous immunoglobulin (IVIG) has been found to
have broad therapeutic applications for the treatment of many
infectious diseases. We found a decrease in the plasma con-
centration of various cytokines following administration of IVIG.
Patients with ANS dsyregulation is the critical timing to received
IVIG infusion. It is possible that a more favorable survival might
have been obtained by earlier therapy and larger doses of IVIG.
Milrinone, cyclic nucleotide phosphodiesterase inhibitor subtype
III, increases cardiac output, and reduces systemic vascular resis-
tance and pulmonary capillary wedge pressure without excessive
increases in myocardial oxygen consumption. EV71-associated
PE patients treat with milrinone is associated with signiﬁcantly
decreased mortality by attenuated sympathetic activity and
cytokine production. Controlled clinical trials are ongoing to
conﬁrm these observations. A better understanding of the clin-
ical features and management of EV71 BE may shed light on
improving the outcome of severe and complicated EV71 BE.
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The main role of antiviral drug therapy for chronic hepatitis B
(CHB) infection is to suppress the hepatitis B virus (HBV) from
active replication, thereby preventing hepatitis and the com-
plications. Doctors and patients alike wished for achieving HBV
eradication early. This will lower the risk of liver complications
and restore health and quality of life of the CHB patients. From
the healthcare provider point of view, the transmission of HBV
infection can be minimized and the health cost substantially
reduced. Eradication of HBV rarely occurs spontaneously; around
0.5 to 2% among CHB individuals lost HBsAg annually. Newer an-
tiviral drugs have higher efﬁcacy and safety. HBsAg loss over and
above the estimated spontaneous incidence has been reported
after and during therapy. The role of current available antiviral
drugs in the full spectrum of CHB disease can be summarized as
follows.
There are two main categories of antiviral therapy for HBV infec-
tion: (1) interferon-based injections, and (2) oral nucleos(t)ide
analogues. Any HBV disease types with viraemia will beneﬁt from
antiviral therapy that is efﬁcacious, safe and affordable. Most
international and national HBV treatment guidelines focused on
individuals with HBV DNA level over 5 log10 copies/ml (i.e. around
4 log10 IU/L); especially if HBeAg negative; associated with raised
serum ALT; and have evidence of signiﬁcant liver ﬁbrosis. Antivi-
ral therapy is particularly important among males, over middle
age, has family history of cirrhosis and hepatocellular carcinoma
(HCC). The aim is to halt the existing liver damage, hopefully
reverse ﬁbrosis, even cirrhosis, and eliminate the conditions
that favour HCC development. Clinical experience and data do
support such strategy.
